



DEPOSITARY RECEIPTS

NEW DR ANNOUNCEMENT

February 2, 2015

Ascendis Pharma A/S

Ascendis Pharma is a biotechnology pharmaceutical company based in Denmark. The Company is engaged in developing differentiated prodrug versions of high-value drugs. The Company's proprietary TransCon technology is used to generate product candidates that are improved versions of existing drugs for use in the treatment of pediatric growth hormone deficiency, adult growth hormone deficiency, pulmonary arterial hypertension, diabetes and Ophthalmology. The Company creates long acting prodrugs of proteins, peptides and small molecules, suitable for either local or systemic treatment. The Company maintains offices in Palo Alto, California and research and clinical development sites in Heidelberg, Germany and Copenhagen.

Effective Date:	February 2, 2015
Country of Incorporation:	Denmark
Exchange:	NASDAQ Stock Market
Type of ADR Program:	Sponsored - Level III
Ticker Symbol:	ASND
CUSIP Number:	04351P101
Ratio (DR:ORD):	1 : 1
Underlying Share Description:	Ordinary
Industry Classification:	Pharma. & Biotech.
Custodian(s) :	The Bank of New York Mellon

To learn more about ADRs and issuer programs, please call our marketing desks:

New York

Ravi Davis
Adrdesk@bnymellon.com
Tel: 212 815 2267

Hong Kong

Herston Powers
Vice President
herston.powers@bnymellon.com
Tel: 852 2840 9868

London

Damon Rowan
Vice President
damon.rowan@bnymellon.com
Tel: 442071637511

Depository Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations of, and are not guaranteed by BNY Mellon and are subject to investment risks including possible loss of principal amount invested.

This announcement and the information contain herein is provided for general informational purposes only. BNY Mellon does not warrant or guarantee the accuracy, timeliness or completeness of this information. We provide no advice or recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. An offering is made by means of a prospectus only. BNY Mellon is regulated by the FSA.